CNTX — Context Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1842952 ·
Last close
$2.63
Market Cap
$241.64M
52W High
$3.62
52W Low
$2.08
ADV30
857,235
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -9,343,799 | -8,680,572 | 58,859,093 | 54,528,596 | 6,656,718 |
| Dec 2025 | 0 | — | -13,804,646 | -13,025,607 | 68,493,768 | 65,995,228 | 8,020,041 |
| Sep 2025 | 0 | — | -10,610,480 | -9,693,237 | 79,231,160 | 76,938,183 | 6,056,994 |
| Jun 2025 | 0 | — | -9,758,362 | -8,827,510 | 87,152,101 | 83,517,047 | 4,607,779 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-26,385,380
Investing CF
$-2,033,948
Financing CF
$-15,268
CapEx
$-2,033,948
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.46
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-130,903,309
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-39,702,631
Pretax Income TTM
$-36,123,615
Interest Exp TTM
—
Analysts
8
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -39,702,631 | -36,123,615 | 68,493,768 | 8,020,041 | — | -26,385,380 |
| Dec 2024 | 0 | -29,923,900 | -26,725,104 | 98,126,759 | 2,860,497 | — | -14,556,434 |
| Dec 2023 | 0 | -25,072,616 | -23,964,211 | 16,062,735 | 4,191,715 | — | -21,047,618 |
| Dec 2022 | 0 | -14,881,203 | -14,835,939 | 37,965,943 | 3,207,577 | — | -13,549,234 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$840,150
NetIncome TTM
$-13,426,294
OpCashFlow TTM
$0
Assets (Latest)
$98,126,759
Forward EPS
$-0.43
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SLGL | Sol-Gel Technologies Ltd. | $241.77M | $74.50 | — |
| NERV | Minerva Neurosciences, Inc. | $243.19M | $5.22 | — |
| ADAG | Adagene Inc. | $245.79M | $3.72 | — |
| WHWK | Whitehawk Therapeutics, Inc. | $235.89M | $4.77 | — |
| BCYC | BICYCLE THERAPEUTICS PLC | $230.21M | $4.57 | — |
News headlines (Yahoo Finance, 1h cache)
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
2026-05-18 10:45 · Yahoo
Context Therapeutics Reports First Quarter 2026 Operating and Financial Results
2026-05-06 20:18 · Yahoo
Positive Signs As Multiple Insiders Buy Context Therapeutics Stock
2026-04-27 14:15 · Yahoo
Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer
2026-04-02 11:30 · Yahoo
Context Therapeutics Reports Full Year 2025 Operating and Financial Results
2026-03-23 20:16 · Yahoo
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026
2026-03-19 11:30 · Yahoo
Context Therapeutics Outlines Post-ADC T-Cell Engager Strategy, Teases Q2 Claudin 6 Data
2026-03-14 15:32 · Yahoo
Context Therapeutics CEO Teases Q2 Claudin 6 Data, Nectin-4 Clinic Entry at TD Cowen Conference
2026-03-08 20:02 · Yahoo
Context Therapeutics to Participate in Upcoming Investor Conferences
2026-02-09 12:30 · Yahoo
Here's Why We're Not Too Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn Situation
2026-02-05 16:06 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.